CHARLES FLYNN: Open Payments
NPI 1609391598 · CONWAY, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$657 in 31 payments from 11 companies in 2025. Trend: 2023 $588 · 2024 $1,255 · 2025 $657
Food & beverage: $657
| Company | Payments | Amount |
|---|---|---|
| Celgene Corporation | 9 | $176 |
| Novartis Pharmaceuticals Corporation | 8 | $141 |
| ABBVIE INC. | 3 | $96 |
| PFIZER INC. | 3 | $62 |
| TAIHO ONCOLOGY, INC. | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| E.R. Squibb & Sons, L.L.C. | 1 | $30 |
| Merck Sharp & Dohme LLC | 1 | $25 |
| AstraZeneca Pharmaceuticals LP | 1 | $24 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 1 | $19 |
Products named: REBLOZYL, IBRANCE, KISQALI, IMBRUVICA, LUTATHERA, EPKINLY, Fabhalta, LONSURF.
Industry payments across SC — which companies pay providers there.
